Nea Management Company Has Upped Its Epizyme (EPZM) Stake; ZHEJIANG EXPRESSWAY (ZHEXF) Shorts Raised By 62.83%

January 10, 2018 - By Marguerite Chambers

ZHEJIANG EXPRESSWAY (OTCMKTS:ZHEXF) had an increase of 62.83% in short interest. ZHEXF’s SI was 62,200 shares in January as released by FINRA. Its up 62.83% from 38,200 shares previously. With 100 avg volume, 622 days are for ZHEJIANG EXPRESSWAY (OTCMKTS:ZHEXF)’s short sellers to cover ZHEXF’s short positions. It closed at $1.09 lastly. It is down 0.00% since January 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Nea Management Company Llc increased Epizyme Inc (EPZM) stake by 3.19% reported in 2017Q3 SEC filing. Nea Management Company Llc acquired 200,000 shares as Epizyme Inc (EPZM)’s stock rose 39.84%. The Nea Management Company Llc holds 6.46M shares with $123.08 million value, up from 6.26M last quarter. Epizyme Inc now has $969.96 million valuation. The stock increased 12.00% or $1.5 during the last trading session, reaching $14. About 204,910 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 91.85% since January 10, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Zhejiang Expressway Co., Ltd., an investment holding company, invests in, develops, operates, maintains, and manages high grade roads in the PeopleÂ’s Republic of China. The company has market cap of $4.52 billion. The firm operates through Toll Operation, Securities Operation, and Other Operation divisions. It has a 9.65 P/E ratio. The Toll Operation segment engages in the operation and management of high grade roads; and the collection of the expressway tolls.

Since August 24, 2017, it had 1 buy, and 3 insider sales for $2.32 million activity. Another trade for 15,000 shares valued at $252,077 was sold by Ho Peter Tai-Ching. 200,000 shares were bought by MOTT DAVID M, worth $3.05M.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts